Pharmacopeia
Corticosteroids — inhaled
Core pharmacology
- Class Group
Inhaled anti-inflammatory glucocorticoids; examples include budesonide, beclometasone and fluticasone.
- Main Action
Suppress chronic airway inflammation and reduce asthma exacerbations; not a rapid rescue bronchodilator when used alone.
- Mechanism of action
Intracellular glucocorticoid receptor activation changes gene transcription, reducing pro-inflammatory mediators and inflammatory-cell activity in airway mucosa.
- Indications Uses
Foundational anti-inflammatory treatment of asthma; in COPD, use is selective (usually in combination inhalers according to exacerbation risk and phenotype), not universally indicated.
- Absorption
Inhaled drug deposits in lung and oropharynx; pulmonary fraction may enter systemic circulation, while swallowed fraction undergoes drug-specific first-pass metabolism. Deposition and bioavailability vary with product and device.
- Metabolism
For example, budesonide undergoes extensive hepatic first-pass metabolism (about 85–90%) to metabolites with much weaker glucocorticoid activity. Do not generalise this numerical PK to every inhaled steroid.
- Adverse Effects Toxicity
Local oropharyngeal candidiasis, dysphonia and throat irritation; at higher cumulative systemic exposure, adrenal suppression, reduced bone density and other steroid effects. In COPD, pneumonia risk is clinically important.
- Special Points
Rinse mouth/spit after inhalation and use appropriate inhaler technique. Some budesonide-formoterol products are used for anti-inflammatory reliever or MART strategies; ICS monotherapy is not a rapid rescue treatment. Follow National Asthma Council Australia guidelines and product-specific instructions.
Source references
These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.